↓ Skip to main content

LZM008, a proposed tocilizumab biosimilar: Pharmacokinetics, safety, and immunogenicity profiles compared with ACTEMRA® in Chinese healthy male subjects

Overview of attention for article published in Frontiers in Pharmacology, April 2023
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (86th percentile)
  • High Attention Score compared to outputs of the same age and source (98th percentile)

Mentioned by

news
1 news outlet
twitter
4 X users

Readers on

mendeley
4 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
LZM008, a proposed tocilizumab biosimilar: Pharmacokinetics, safety, and immunogenicity profiles compared with ACTEMRA® in Chinese healthy male subjects
Published in
Frontiers in Pharmacology, April 2023
DOI 10.3389/fphar.2023.1111893
Pubmed ID
Authors

Guoying Cao, Jingjing Wang, Jinjie He, Yingying Hu, Haijing Yang, Linling Que, Xianghong Gu, Jicheng Yu, Xiaojie Wu, Jufang Wu, Wei Fang, Qing He, Jing Zhang

X Demographics

X Demographics

The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 4 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 4 100%

Demographic breakdown

Readers by professional status Count As %
Unspecified 1 25%
Student > Doctoral Student 1 25%
Unknown 2 50%
Readers by discipline Count As %
Unspecified 1 25%
Medicine and Dentistry 1 25%
Unknown 2 50%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 May 2023.
All research outputs
#3,103,183
of 23,760,369 outputs
Outputs from Frontiers in Pharmacology
#1,329
of 17,404 outputs
Outputs of similar age
#49,489
of 374,417 outputs
Outputs of similar age from Frontiers in Pharmacology
#15
of 860 outputs
Altmetric has tracked 23,760,369 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 17,404 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.1. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 374,417 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 86% of its contemporaries.
We're also able to compare this research output to 860 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 98% of its contemporaries.